These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 335903)

  • 1. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects.
    Watson SJ; Berger PA; Akil H; Mills MJ; Barchas JD
    Science; 1978 Jul; 201(4350):73-6. PubMed ID: 351804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of naloxone and schizophrenic auditory hallucinations.
    Freeman CP; Fairburn CG
    Psychol Med; 1981 May; 11(2):405-7. PubMed ID: 7022531
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of effect on naloxone on schizophrenic symptoms.
    Janowsky DS; Segal DS; Bloom F; Abrams A; Guillemin R
    Am J Psychiatry; 1977 Aug; 134(8):926-7. PubMed ID: 879360
    [No Abstract]   [Full Text] [Related]  

  • 6. Negative naloxone effects in schizophrenic patients.
    Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
    Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous naloxone administration in schizophrenia and affective illness.
    Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ
    Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indication of an antipsychotic action of the opiate antagonist naloxone.
    Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone-induced reversal of schizophrenic hallucinations.
    Gunne LM; Lindström L; Terenius L
    J Neural Transm; 1977; 40(1):13-9. PubMed ID: 319204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated naloxone administration in schizophrenia.
    Verhoeven WM; van Praag HM; van Ree JM
    Psychiatry Res; 1984 Aug; 12(4):297-312. PubMed ID: 6594713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Administration of naloxone in schizophrenic psychoses and manic syndromes].
    Verhoeven WM; van Praag HM; de Jong JT
    Ned Tijdschr Geneeskd; 1981 Apr; 125(14):532-7. PubMed ID: 6112715
    [No Abstract]   [Full Text] [Related]  

  • 12. Naloxone in chronic schizophrenia.
    Volavka J; Mallya A; Baig S; Perez-Cruet J
    Science; 1977 Jun; 196(4295):1227-8. PubMed ID: 860138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone in schizophrenia.
    Skrabanek P
    Lancet; 1982 Dec; 2(8310):1270. PubMed ID: 6128561
    [No Abstract]   [Full Text] [Related]  

  • 14. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.
    Pickar D; Vartanian F; Bunney WE; Maier HP; Gastpar MT; Prakash R; Sethi BB; Lideman R; Belyaev BS; Tsutsulkovskaja MV; Jungkunz G; Nedopil N; Verhoeven W; van Praag H
    Arch Gen Psychiatry; 1982 Mar; 39(3):313-9. PubMed ID: 6121545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study.
    Pickar D; Bunney WE; Douillet P; Sethi BB; Sharma M; Vartanian ME; Lideman RP; Naber D; Leibl K; Yamashita I
    Biol Psychiatry; 1989 Feb; 25(4):440-8. PubMed ID: 2539206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
    Naber D; Leibl K
    Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial.
    Jungkunz G; Nedopil N; Rüther E
    Pharmacopsychiatry; 1984 May; 17(3):76-8. PubMed ID: 6739537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone-induced reduction of schizophrenic symptoms.
    Jørgensen HA; Cappelen C
    Acta Psychiatr Scand; 1982 May; 65(5):370-4. PubMed ID: 6126068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone versus placebo in treatment of septic shock.
    DeMaria A; Carven DE; Heffernan JJ; McIntosh TK; Grindlinger GA; McCabe WR
    Lancet; 1985 Jun; 1(8442):1363-5. PubMed ID: 2861315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of naloxone on the state of patients with endogenous psychoses.
    Lideman RR; Panteleeva GP; Tsutsul'kovskaya MYa ; Vartanyan FE; Belyaev BS
    Neurosci Behav Physiol; 1984; 14(6):471-5. PubMed ID: 6097836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.